Amatech

ApplicationBeijing, ChinaFounded 2011· One of 702 Application companies tracked by AMPulse

Pan-vascular interventional device company building a diagnosis-to-treatment stack via multi-axis 3D-printed bioresorbable stents and CO2 angiography systems.

CEO / Founder: Liu Qing
Team Size: 51-200
Stage: Growth Stage
Total Funding: $79M+
Latest Round: Series D
Key Investors: Zhesheng Collaborative Life Health Fund (浙生协同生命健康基金), Henan Key Intellectual Property Fund, Global Hedge Fund Management, SDIC Venture Capital, China Reform Holdings, Beijing State-owned Assets Management (BSAM), Haidian Science & Technology Financial Capital Group

Technology & Products

Key Products

AMSorb / bioresorbable coronary scaffolds, Bioresorbable peripheral vascular stents, Jetfall / 星落雨 CO2 contrast pressure injection set (Class III), Bioresorbable biliary stents, PLCL biodegradable medical polymers, 3D multi-axis precision printing platform for absorbable implants

Technical position · AMPulse analysis

Proprietary 3D printing process allows for complex stent geometries and optimized mechanical properties that are difficult to achieve with traditional manufacturing, enabling better biocompatibility and degradation control.

Differentiation

Value Proposition

Combines zero-iodine CO2 contrast (safer for renal-risk/iodine-allergic patients) with multi-nozzle 3D-printed bioresorbable scaffolds that temporarily support vessels then dissolve—diagnosis + treatment for pan-vascular care.

How They Differentiate

Proprietary multi-nozzle precision 3D printing technology that enables thinner struts and complex geometries compared to traditional laser-cut polymer stents.

Market & Competition

Target Customers

Hospitals, cardiovascular surgeons, and patients with coronary or peripheral artery diseases.

Industry Verticals

Medical Devices, Healthcare, 3D Printing

Competitors

Lepu Medical (NeoVas), MicroPort Scientific (Firesorb), Biotronik (Magmaris)

Growth & Milestones

Growth Metrics

First commercial product live: Jetfall CO2 contrast Class III (China 2026) with CE/overseas sales in 20+ countries; 3D-printed absorbable stents in late clinical/registration; multiple NMPA innovation green-channel products; post-D valuation >¥1.5B.

Major Milestones

World's first 3D-printed biodegradable vascular stent to enter clinical trials (2019), Completed Series D funding of over 200 million RMB (2022), Designated as a National High-Tech Enterprise in China

Notable Customers

Fuwai Hospital, Beijing Anzhen Hospital

https://www.ametcorp.com

Funding rounds

Series D>$28M (超2亿元 RMB)2026-04Lead: Zhesheng Collaborative Life Health Fund · Source: 投资界 / 证券时报 / 21世纪经济报道
Series D$28.2M2022-12Lead: SDIC Venture Capital · Source: Nanjixiong / IT Juzi
Series C$14.1M2020-07Lead: China Reform Holdings · Source: IT Juzi
Series B$7.0M2017-09Lead: SDIC Venture Capital · Source: Web
Series A$1.4M2014-06Lead: Haidian Science & Technology Financial Capital Group · Source: IT Juzi

Why this company matters

AMPulse analysis, not a company disclosure

Amatech occupies a distinctive position in the interventional cardiology market by replacing permanent metal stents with bioresorbable scaffolds that provide temporary vessel support and then degrade. This approach addresses the long-term risks of late stent thrombosis and chronic inflammation associated with conventional drug-eluting stents. The company has moved beyond the laser-cutting methods used by most polymer-stent makers, instead developing a proprietary multi-nozzle 3D printing process designed for mass production of bioresorbable vascular stents.

The core product line includes the AMSorb Bioresorbable Coronary Scaffold, bioresorbable peripheral vascular stents, and a 3D printing medical device manufacturing platform. The multi-nozzle process enables thinner struts and complex geometries that are difficult to achieve with traditional manufacturing, improving biocompatibility and allowing precise control over degradation rates. Amatech holds over 50 domestic and international patents related to 3D printing technology and bioresorbable medical materials.

Target customers include hospitals and cardiovascular surgeons treating coronary or peripheral artery diseases. The company has clinical trial collaborations with Fuwai Hospital and Beijing Anzhen Hospital. Amatech's AMSorb scaffold was the world's first 3D-printed biodegradable vascular stent to enter clinical trials in 2019, and multiple products have received NMPA Green Channel status for expedited regulatory review. The company completed a Series D round of over 200 million RMB in 2022, backed by investors including SDIC Venture Capital, China Reform Holdings, and Beijing State-owned Assets Management.

Amatech competes with Lepu Medical's NeoVas, MicroPort Scientific's Firesorb, and Biotronik's Magmaris in the bioresorbable scaffold space. Its differentiation rests on the proprietary multi-nozzle 3D printing technology, which allows for thinner struts and more complex geometries than laser-cut polymer stents. The key open question is whether the company can scale manufacturing to compete with established players on cost and reliability, and whether its clinical data will demonstrate superiority over existing BVS products in long-term outcomes.